The CD20 inhibitor Ocrevus (ocrelizumab) rapidly depletes immune B-cells in people with multiple sclerosis (MS), as expected, but ongoing treatment also leads to changes in immune T-cells, a new study […]
The post Ocrevus rapidly depletes B-cells, then alters T-cells in MS patients appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com